Trends in incidence and prevalence of patients living long-term with de novo metastatic incurable cancer: a retrospective cohort study
Authors:
- Ruben BoumaRBRuben Bouma
- Olaf P. GeerseOGOlaf P. Geerse
- Natasja J. H. RaijmakersNRNatasja J. H. Raijmakers
- Heidi P. FransenHFHeidi P. Fransen
- Lia van ZuylenLZLia van Zuylen
- Anna K. L. ReynersARAnna K. L. Reyners
- Kristel van AsseltKAKristel van Asselt
- Maatje D. A. van GastelMGMaatje D. A. van Gastel
- Daan BrandenbargDBDaan Brandenbarg
- Mariken E. StegmannMSMariken E. Stegmann
- 6 October 2026
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- p. 1-9
Abstract
Background Therapeutic advances have improved the survival of incurable cancer patients, creating a growing population living long-term with incurable cancer. However, little is known about their epidemiological characteristics. We aimed to examine trends in annual incidence and prevalence among patients living long-term with de novo metastatic incurable cancer in the Netherlands and to describe additional relevant sociodemographic and clinical characteristics among patients diagnosed in recent years. Methods A population-based, retrospective cohort study using data from the Netherlands Cancer Registry was performed. Adults (≥18 years) diagnosed with de novo metastatic solid tumors in 2000–2021 who survived ≥2 years after their diagnosis were included. Annual incidence, prevalence, key demographic, and tumor characteristics were calculated. Results Annual incident cases of patients living long-term with de novo metastatic incurable cancer increased from 1298 (2000) to 5398 (2021), representing 12.0–22.6% of incurable cancer diagnoses. In February 2024, at least 18,466 patients in the Netherlands were living long-term with de novo metastatic incurable cancer (1 per 1000 inhabitants). Mean age was 64 years (SD 12), 59.4% were male, and 55.8% (n = 10,310) were alive 2- < 5 years after diagnosis, 31.0% (n = 5721) 5- < 10 years, and 13.2% (n = 2435) ≥ 10 years. The most common tumor types were prostate (35.6%), lung (20.2%), breast (14.4%), and colorectal cancer (6.3%). Conclusion Substantial increases in the incidence and prevalence were identified, reflecting a shift toward prolonged survival within the incurable cancer population. Greater awareness and research are needed to inform care for this emerging group.Keywords
Funding Information
- Friends of Integrative Oncology Care
This publication has 34 references indexed in Scilit:
- International comparisons of survival after recurrent metastatic breast cancer in four countries: A population-based studyThe Breast, 2026
- Estimating the number of people living with metastatic breast cancer: a population-based retrospective cohort study using linked health dataThe Lancet Regional Health - Western Pacific, 2026
- Perspectives of patients, partners, primary and hospital-based health care professionals on living with advanced cancer and systemic treatmentJournal of Cancer Survivorship, 2024
- Survivorship care for people affected by advanced or metastatic cancer: MASCC-ASCO standards and practice recommendationsSupportive Care in Cancer, 2024
- Living in the twilight zone: a qualitative study on the experiences of patients with advanced cancer obtaining long-term response to immunotherapy or targeted therapyJournal of Cancer Survivorship, 2022
- ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in EuropeAnnals of Oncology, 2022
- Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapyJournal of Cancer Survivorship, 2021
- Experiences and needs of patients with incurable cancer regarding advance care planning: results from a national cross-sectional surveySupportive Care in Cancer, 2020
- Cancer survivorship and palliative care: Shared progress, challenges, and opportunitiesCancer, 2018
- Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapySupportive Care in Cancer, 2018